For research use only. Not for therapeutic Use.
Eptifibatide acetate(Cat No.:I006694)is a glycoprotein IIb/IIIa inhibitor used as an antiplatelet medication to reduce the risk of blood clots in patients with acute coronary syndrome (ACS) or undergoing percutaneous coronary interventions (PCI), such as angioplasty. By blocking the platelet glycoprotein receptor, eptifibatide prevents platelet aggregation, thus reducing the likelihood of thrombus formation and improving blood flow. It is typically administered intravenously in a hospital setting. Side effects may include bleeding, hypotension, or thrombocytopenia. Close monitoring is necessary during treatment to manage these risks effectively.
Catalog Number | I006694 |
CAS Number | 188627-80-7 (free base). |
Synonyms | Eptifibatide acetate; Integrilin; ptifibatide; Integrelin;;2-((3R,11S,17S,20S,25aS)-20-((1H-indol-3-yl)methyl)-3-carbamoyl-11-(4-guanidinobutyl)-1,9,12,15,18,21-hexaoxodocosahydro-7H-pyrrolo[2,1-g][1,2]dithia[5,8,11,14,17,20]hexaazacyclotricosin-17-y |
Molecular Formula | C35H49N11O9S2 |
Purity | ≥95% |
Target | Integrin |
Solubility | Soluble in DMSO, not in water |
Storage | 0 - 4°C for short term or -20 °C for long term |
IUPAC Name | 2-[(3S,6S,12S,20R,23S)-20-carbamoyl-12-[4-(diaminomethylideneamino)butyl]-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,22-hexaoxo-17,18-dithia-1,4,7,10,13,21-hexazabicyclo[21.3.0]hexacosan-6-yl]acetic acid |
InChI | InChI=1S/C35H49N11O9S2/c36-30(51)25-18-57-56-13-10-27(47)42-22(8-3-4-11-39-35(37)38)31(52)41-17-28(48)43-23(15-29(49)50)32(53)44-24(14-19-16-40-21-7-2-1-6-20(19)21)34(55)46-12-5-9-26(46)33(54)45-25/h1-2,6-7,16,22-26,40H,3-5,8-15,17-18H2,(H2,36,51)(H,41,52)(H,42,47)(H,43,48)(H,44,53)(H,45,54)(H,49,50)(H4,37,38,39)/t22-,23-,24-,25-,26-/m0/s1 |
InChIKey | CZKPOZZJODAYPZ-LROMGURASA-N |
SMILES | C1C[C@H]2C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N2C1)CC3=CNC4=CC=CC=C43)CC(=O)O)CCCCN=C(N)N)C(=O)N |